Evercore ISI analyst Joshua Schimmer raised the firm’s price target on Ventyx Biosciences to $65 from $50 and keeps an Outperform rating on the shares following what the firm called "another masterful presentation pulling together disparate data points to provide a clear and crisp outlook across its portfolio." While stating that it will be "keeping a close watch on" other assets and indications, for now the firm is only increasing its S1P1 estimates for UC, driving its increased price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTYX:
- Ventyx Biosciences announces pipeline updates, strategic priorities
- Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day
- Ventyx Biosciences management to meet with Piper Sandler
- Ventyx Biosciences appoints Allison Hulme, Ph.D. to board
- Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors
